Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Open Orphan Plc ( (GB:HVO) ).
hVIVO plc has secured a £2 million contract with a new biopharmaceutical client to conduct the final stage of a human metapneumovirus (hMPV) characterisation study, following a successful pilot trial. This reflects the company’s strategic positioning as a leader in human challenge trials, and the growing demand for hMPV drug development services amid rising global concerns about the virus. The study aims to expand existing data and build a robust model for future hMPV human challenge trials, which could facilitate faster market approvals and address significant unmet medical needs due to the lack of approved vaccines or therapeutics for hMPV.
More about Open Orphan Plc
hVIVO plc is a rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world’s ten largest biopharma companies. hVIVO specializes in conducting human challenge trials across multiple infectious and respiratory indications, utilizing its state-of-the-art quarantine facility in London. Additionally, it offers virology and immunology laboratory services and operates a 120-bed capacity in Germany for early-phase clinical trial services through its subsidiary, CRS.
YTD Price Performance: -12.20%
Average Trading Volume: 3,338,758
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £122.5M
See more data about HVO stock on TipRanks’ Stock Analysis page.
